A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

Titre officiel

A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

Sommaire:

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation) and to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination with ipilimumab versus ipilimumab monotherapy (for dose expansion).

Description de l'essai

Primary Outcome:

  • Number of Participants with Adverse Events (AEs)
  • Number of Participants with Serious Adverse Events (SAEs)
  • Number of Participants With Adverse Events Including Dose Limiting Toxicity
  • Number of Participants with AEs resulting in Discontinuation
  • Number of Participants with AEs resulting in Death
  • Number of Participants with AEs resulting in Laboratory Abnormalities
  • Objective Response Rate (ORR)
Secondary Outcome:
  • Duration of response (DOR)
  • Median PFS
  • Median Overall Survival (OS)
  • Number of Participants with Anti-Drug Antibodies (ADA)-Positivity
  • Progression Free Survival rates (PFS rates)
  • Overall Survival Rates (OS rates)
  • Objective Response Rate (ORR)

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer